IHC staining results showed that YBX1 was higher in both the cytoplasm and nucleus of hepatocytes in patients with MASLD than that of the control group (Figure 1B and Supplemental Figure 1A, S1A). This evidence concerns the gene YBX1 and metabolic dysfunction-associated steatotic liver disease.